<DOC>
	<DOCNO>NCT01707043</DOCNO>
	<brief_summary>This open label , investigator-blinded , cross , prospective , single center study subject plaque psoriasis . Taclonex® ( calcipotriene 0.005 % betamethasone dipropionate 0.064 % ) Ointment Taclonex Scalp® ( calcipotriene 0.005 % betamethasone dipropionate 0.064 % ) Topical Suspension apply topically daily . The primary objective ass patient preference Taclonex® ( calcipotriene 0.005 % betamethasone dipropionate 0.064 % ) Ointment compare Taclonex Scalp® ( calcipotriene 0.005 % betamethasone dipropionate 0.064 % ) Topical Suspension treatment plaque psoriasis . The secondary objective ass efficacy Taclonex® ( calcipotriene 0.005 % betamethasone dipropionate 0.064 % ) Ointment compare Taclonex Scalp® ( calcipotriene 0.005 % betamethasone dipropionate 0.064 % ) Topical Suspension treatment plaque psoriasis .</brief_summary>
	<brief_title>Patient Preference Taclonex Ointment Taclonex Scalp Suspension Adult Subjects With Psoriasis Vulgaris</brief_title>
	<detailed_description>- Following satisfaction entry criterion , subject Baseline/Screening visit randomize 1:1 receive either Taclonex® ( calcipotriene 0.005 % betamethasone dipropionate 0.064 % ) Ointment Taclonex Scalp® ( calcipotriene 0.005 % betamethasone dipropionate 0.064 % ) Topical Suspension use daily three day affect area body , exclude face intertriginous area . Subjects aware product use . Investigators remain blinded . - Subjects randomize use either ointment scalp suspension three day , cross use product three day . - Each medication use within FDA-approved label treatment plaque psoriasis subject age 18 old . Subjects may treat area face , axilla groin study . - Subjects return study center Day 3 ( cross ) Day 6 ( end study ) . At visit , subject score status representative target lesion severity Investigator Global Assessment current psoriasis condition . - At Day 3 Day 6 visit subject complete questionnaire psoriasis treatment preference . - Pregnancy test do female childbearing potential Baseline/Screening . - Adverse event monitor visit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Subject male female , age 18 old , good health . Subject plaquetype psoriasis history current pustular , erythrodermic guttate psoriasis . Subject capable understanding willing provide sign dated write voluntary informed consent protocol specific procedure perform . The percentage overall body surface involvement 110 % trunk extremity amenable topical treatment le 100g topical medication per week . The subject investigator global assessment mild moderate plaque psoriasis ( severity index 2 3 5 point scale ) . The subject able complete study comply study instruction , include attend study visit . If female subject childbearing potential , subject negative urine pregnancy test . Sexually active woman childbearing potential participating study must use medically acceptable form contraception ( include barrier method , oral contraception , injectable implantable method , intrauterine device ) least three month prior entry study . A woman childbearing potential define one biologically capable become pregnant . Abstinence consider acceptable method contraception . Subject use experimental drug device least one month prior Baseline . Subject use systemic corticosteroid , phototherapy , retinoids , methotrexate , cyclosporine , immunosuppressive agent biologics therapy ( ie , alefacept , etanercept , efalizumab ) within four week Baseline . Subject use topical therapy , corticosteroid therapy , topical vitamin D analog calcineurin inhibitor , tazarotene within two week prior Baseline visit ( eg , tar , anthralin , salicylic acid , lactic acid , urea preparation ) . Subject serious skin disorder chronic medical condition well control . Subject clinically relevant abnormal vital sign finding physical examination . Subject major illness within 30 day prior Baseline visit . Subject history immunocompromising disease . Subject pregnant nursing . Pregnant nursing female allow study , female childbearing potential pregnancy test Baseline . Subject skin condition disease may require concurrent therapy may confound evaluation ; history hypersensitivity formulation component ; atopic dermatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>taclonex</keyword>
	<keyword>crossover</keyword>
</DOC>